Clinical and Biological Digestive Peritoneal Carcinomatosis Data Base From the French National Network of Peritoneal Surface Malignancies
NCT02823860 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2186
Last updated 2025-12-19
Summary
To access to good quality biological samples is a prerequisite for high level translational research. The BIG-RENAPE study has been established by the French hyperthermic intraperitoneal chemotherapy centers involved in the management of peritoneal surface malignancies.
The main BIG-RENAPE study aim is to create a large multicentric and prospective repository for biological and tissue samples, which will provide a source of materials for a wide array of health related research studies - BIG-RENAPE Biobank-based research: i) validating known and promising biomarkers; ii) identifying new predictive and prognostic factors; iii) evaluating the impact of current health care strategies; iv) standardizing diagnostic and therapeutic management through guidelines; v) developing new drugs.
The BIG-RENAPE Biobank is certified according to NFS 96-900 as a service of processing, storage and transfer of high quality biological (plasma, serum, buffy coat) and tissue (formalin-fixed-paraffin-embedded) samples. Biospecimens are collected at each stage of diagnostic and therapeutic care. The patient and his derivates are anonymized and registered in a national web database reporting disease status, treatments, surgical procedures, pathological diagnosis, quality of life's assessment and long term follow-up. All participants have given their informed consent before any sample. The BIG-RENAPE study was approved by the local Ethical Committee, based on the assessed compliance to French regulatory rules.
Conditions
- Digestive Peritoneal Carcinomatosis
Interventions
- OTHER
-
Collection of biospecimens and Quality of Life (QoL) assessment
Serum, plasma, buffy coat and formalin-fixed-paraffin-embedded (FFPE). Biospecimens are collected at various stages of diagnostic and therapeutic care.All patients fill out questionnaires of Health related quality of life (QLQ-C30 + QLQ-CR29/STO22, Hospital Anxiety and Depression scale - HAD) and social-demographic survey (Medical Outcome Studies - Social Support Survey- MOS-SSS).
Sponsors & Collaborators
-
Hospices Civils de Lyon
lead OTHER
Principal Investigators
-
Olivier Glehen, Pr · Hospices Civils de Lyon - Centre Hospitalier Lyon Sud - Service de Chirurgie Générale et Digestive - 165 chemin du grand Revoyet - 69495 Pierre-Bénite, France
Study Design
- Allocation
- NA
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-02-12
- Primary Completion
- 2022-10-13
- Completion
- 2022-10-13
Countries
- France
Study Locations
More Related Trials
-
Onco-geriatric Database of Patients With Pancreatic Cancer
NCT02858141 ·Status: UNKNOWN
-
Convertases and Pancreatic Cancer: Cohort of Patients Treated for Pancreatic Adenocarcinoma
NCT06705335 ·Status: RECRUITING
-
Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors
NCT01692873 ·Status: COMPLETED ·Phase: NA
-
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
NCT06922591 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES Study)
NCT04929015 ·Status: SUSPENDED ·Phase: NA
-
Prospective Registry of Young-Adult Patients Diagnosed With Pancreatic Cancer
NCT05845801 ·Status: RECRUITING
-
Anatomical-Clinical Base of Adenocarcinoma Pancreatic
NCT06128343 ·Status: RECRUITING
-
Profiling Program of Advanced/Metastatic Pancreatic Cancer Patients
NCT05380414 ·Status: RECRUITING ·Phase: NA
-
Institut Paoli-Calmettes Pancreatic Neoplasms Database
NCT02869581 ·Status: RECRUITING
-
The Lyon Real World Evidence in Metastatic NeuroEndocrine Tumours
NCT03863106 ·Status: UNKNOWN
-
Construction and Evaluation of China's Advanced Pancreatic Tumor Big Data Center
NCT05141656 ·Status: UNKNOWN
-
Pancreatic Adenocarcinoma Gene Environment Risk Study
NCT00912717 ·Status: RECRUITING
-
Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, BTC or NEN
NCT06735560 ·Status: RECRUITING ·Phase: NA
-
Stereotactic Radiotherapy in Locally Advanced Pancreatic Cancer With Different Biological Effective Doses
NCT04603586 ·Status: COMPLETED ·Phase: NA
-
Debulking and Chemotherapy With or Without Intraperitoneal Chemotherapy to Treat Peritoneal Carcinomatosis
NCT00052962 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Study of BRCA and DNA Damage Repair Genes in Blood Samples of Chinese Pancreatic Cancer Patients
NCT05138302 ·Status: UNKNOWN
-
Bonds Between Circulating Tumoral ADN (ctDNA) and the Development of Peritoneal Carcinomatosis for Patients Under PIPAC
NCT04766502 ·Status: COMPLETED ·Phase: NA
-
Two Chemotherapy Regimens Plus or Minus Bevacizumab
NCT03351296 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of Induction Chemotherapy Followed by Radiochemotherapy in Locally Advanced Pancreatic Cancer
NCT02984501 ·Status: COMPLETED ·Phase: PHASE2
-
Biological and Clinical Database for Pancreatic Adenocarcinoma
NCT02818829 ·Status: ACTIVE_NOT_RECRUITING
-
Project Survival-Prospective Biomarker Discovery
NCT02781012 ·Status: UNKNOWN
-
Different Patterns of Target Delineation in SBRT for Locally Advanced Pancreatic Cancer
NCT04699539 ·Status: COMPLETED ·Phase: NA
-
Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis
NCT02869802 ·Status: RECRUITING
-
Diffusion MRI for Pancreatic Adenocarcinoma
NCT02896946 ·Status: COMPLETED ·Phase: NA
-
A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer
NCT05026905 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2